COPD is a world-wide health problem of increasing prevalence. Non-invasive markers of disease phenotype, severity and rate of progression of the disease, markers characterizing exacerbations of COPD are badly needed. We propose to analyze ultrafiltered exhaled air samples, to establish optimal protocols for sample collection following a FEV1 maneuver, to survey lipids including phospholipids, eicosanoids, steroids, nucleosides, proteins and peptides as markers of potential disease (activity). We propose to establish quantitative mass spectroscopic techniques (using stable isotope dilution protocols) for target marker assays. We propose to investigate stable COPD patients before and during supplemental continuous flow oxygen treatment, before and during alpha-l-antitrypsin infusion therapy, before and after smoking cessation and before and after lung transplantation.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL072235-04
Application #
6923700
Study Section
Special Emphasis Panel (ZHL1-CSR-H (S1))
Program Officer
Croxton, Thomas
Project Start
2002-09-26
Project End
2007-07-31
Budget Start
2005-08-01
Budget End
2007-07-31
Support Year
4
Fiscal Year
2005
Total Cost
$317,015
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Lee, Ji-Hyun; Hanaoka, Masayuki; Kitaguchi, Yoshiaki et al. (2012) Imbalance of apoptosis and cell proliferation contributes to the development and persistence of emphysema. Lung 190:69-82
Demura, Yoshiki; Taraseviciene-Stewart, Laima; Scerbavicius, Robertas et al. (2004) N-acetylcysteine treatment protects against VEGF-receptor blockade-related emphysema. COPD 1:25-32